Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent

✍ Scribed by Soo-Hyun Kim; Dongho Kim; Dong-Wook Kim; Hyun-Gyung Goh; Se-Eun Jang; Jeong Lee; Wan-Seok Kim; Il-Young Kweon; Sa-Hee Park

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 202 KB
• Volume: 27
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.894

✦ Synopsis

Abstract

Despite durable responses to imatinib in chronic myeloid leukaemia (CML), mutations in Bcr‐Abl kinase domain (KD) are known to induce imatinib resistance and cause poor clinical outcome. We characterized Bcr‐Abl KD mutations in 137 Korean CML patients with imatinib resistance (n = 111) or intolerance (n = 26) using allele specific oligonucleotide polymerase chain reaction (PCR) and direct sequencing. Seventy (51%) patients harboured 81 mutations of 20 different types with increasing prevalence in advanced phase. Nine (13%) patients had multiple mutations. No mutation was found in intolerant patients. T315I was the most common mutation and P‐loop was the hottest spot in Bcr‐Abl KD. Patients harbouring P‐loop mutation, T315I, or multiple mutations showed poor overall survival and progression free survival compared with patients harbouring other mutations. Survival analysis according to disease phase of mutation being detected and type of mutations provided correlation between P‐loop or T315I mutation and poor overall survival in blast crisis, but not in accelerated phase (AP) or chronic phase (CP), indicating poor clinical outcome of particular mutations depends on disease phase. CML patients with imatinib resistance showed high rate (63%) of mutations in Bcr‐Abl KD and therefore CML patients who do not respond to imatinib should be the candidates for mutation screening as molecular monitoring. Copyright © 2009 John Wiley & Sons, Ltd.